natgillin/translations-raw huggingface dataset:
In vitro data indicate that ketoconazole is an inhibitor of CYP1A2 and does not significantly inhibit CYP 2A6 and 2E1.
Podatki in vitro kažejo, da je ketokonazol zaviralec CYP1A2, encimov CYP 2A6 in 2E1 pa ne zavira pomembno.
In vitro data indicate that ledipasvir may be a weak inducer of metabolising enzymes such as CYP3A4, CYP2C and UGT1A1.
Podatki in vitro nakazujejo, da bi lahko bil ledipasvir šibak induktor presnovnih encimov, kot so CYP3A4, CYP2C in UGT1A1.
In vitro data indicate that lipegfilgrastim is has little or no direct or immune system-mediated effects on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4/5 activity.
Podatki in vitro kažejo, da lipegfilgrastim neposredno ali preko imunskega sistema le malo ali sploh ne učinkuje na aktivnost encimov CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 in CYP3A4/5.
In vitro data indicate that selexipag could be an inducer of both CYP3A4 and CYP2C9 in the intestine.
Podatki in vitro kažejo, da bi lahko bil seleksipag v črevesju induktor tako CYP3A4 kot CYP2C9.
In vitro data indicate that the following species are not susceptible to ceftolozane/tazobactam:
Podatki in vitro kažejo, da naslednje vrste niso občutljive na ceftolozan/tazobaktam:
In vitro data indicate that ulipristal acetate may be an inhibitor of P-gp at clinically relevant concentrations.
Podatki in vitro kažejo, da je lahko ulipristalacetat v klinično pomembnih koncentracijah zaviralec P- glikoproteina.
In vitro data indicated that drug-drug interactions with afatinib due to inhibition of OATB1B1, OATP1B3, OATP2B1, OAT1, OAT3, OCT1, OCT2, and OCT3 transporters are considered unlikely.
Podatki in vitro so pokazali, da medsebojni učinki afatiniba z drugimi zdravili zaradi zaviranja prenašalcev OATB1B1, OATP1B3, OATP2B1, OAT1, OAT3, OCT1, OCT2 in OCT3 niso verjetni.
In vitro data indicated that drug-drug interactions with afatinib due to inhibition of UGT1A1 are considered unlikely.
Podatki in vitro so pokazali, da medsebojni učinki z afatinibom zaradi zaviranja UGT1A1 niso verjetni.
In vitro data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite but the main contributing isoenzyme has not been confirmed in vivo..
Podatki in vitro kažejo, da so encimi CYP2C9, CYP2C19 in CYP3A4 sposobni katalizirati nastanek O-desmetilnega presnovka, vendar glavni prispevek izoencimov in vivo ni bil potrjen.
In vitro data suggest that brivaracetam has a low interaction potential.
Podatki in vitro kažejo, da ima brivaracetam nizek interakcijski potencial.
In vitro data suggest that dasatinib has the potential to prolong cardiac ventricular repolarisation (QT Interval) (see section 5.3).
Podatki, pridobljeni in vitro kažejo, da je uporaba dasatiniba lahko povezana s podaljšanjem repolarizacije ventriklov (interval Q-T) (glejte poglavje 5.3).
In vitro data suggest that the potential for pharmacokinetic drug interactions related to CYP interaction and protein binding is low for both liraglutide and insulin degludec.
In vitro podatki kažejo, da je potencial liraglutida in insulina degludek za farmakokinetične interakcije, povezane z interakcijo s CYP in vezavo na beljakovine, majhen.
In vitro data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by uridine 5'-diphosphoglucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7.
Podatki in vitro kažejo, da je glavna presnovna pot empagliflozina pri ljudeh glukuronidacija z uridin 5‘-difosfo-glukuronoziltransferazami UGT1A3, UGT1A8, UGT1A9 in UGT2B7.
In vitro data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by uridine 5'-diphosphoglucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7.
Podatki in vitro kažejo, da je glavna presnovna pot empagliflozina pri ljudeh glukuronidacija z uridinom 5‘-difosfo-glukuronoziltransferazami UGT1A3, UGT1A8, UGT1A9 in UGT2B7.
In vitro data suggest that the sucrose and starch components of the drug substance can be digested to glucose and fructose, and maltose and glucose, respectively.
Podatki, pridobljeni in vitro, kažejo, da se saharoza in škrob iz zdravilne učinkovine lahko presnavljata v glukozo in fruktozo oziroma maltozo in glukozo.
In vitro data using human liver microsomes indicate the formation of small amounts of N- demethylated topotecan.
V raziskavi in vitro, v kateri so uporabili mikrosome človeških jeter, so opazili nastanek majhne količine N-demetiliranega topotekana.
In vitro dermal absorption into human skin was studied using Ameluz containing radiolabelled 5- aminolaevulinic acid.
Z zdravilom Ameluz, ki je vsebovalo radioaktivno označeno 5-aminolevulinsko kislino, so preučevali dermalno absorpcijo v človeško kožo in vitro.
In vitro erythrocyte concentrations of 14C-mirabegron were about 2-fold higher than in plasma.
In vitro je bila koncentracija 14C-mirabegrona v eritrocitih pribliţno 2-krat večja kot v plazmi.
In vitro eslicarbazepine is a weak inducer of CYP3A4 and UDP-glucuronyl transferases.
Eslikarbazepin je in vitro šibek spodbujevalec encima CYP3A4 in UDP- glukuroniltransferaz.
In vitro evaluation indicated that trifluridine and FTY had no inductive effect on human CYP isoforms (see section 5.2).
Vrednotenje in vitro je pokazalo, da trifluridin in FTY nimata inducirajočega učinka na humane izoforme CYP (glejte poglavje 5.2).
In vitro evaluation indicated that trifluridine and FTY had no inductive effect on human CYP1A2, CYP2B6 or CYP3A4/5.
Vrednotenje in vitro je pokazalo, da trifluridin in FTY nimata inducirajočega učinka na humane CYP1A2, CYP2B6 ali CYPA4/5.
In vitro experiments have shown that the hepatic metabolism of saquinavir becomes saturable at concentrations above 2 g/ml.
In vitro poskusi so pokazali, da se presnova sakvinavirja v jetrih zasiti pri koncentracijah nad 2 µg/ml.
In vitro experiments show that lumacaftor is a substrate for Breast Cancer Resistance Protein (BCRP).
Poskusi in vitro kažejo, da je lumakaftor substrat beljakovine odpornosti pri raku dojke (Breast Cancer Resistance Protein - BCRP).
In vitro functional studies of human vacuolated macrophages indicated all functions tested were retained.
In vitro funkcijske raziskave humanih vakuoliziranih makrofagov so pokazale, da so se vse testirane funkcije ohranile.
In vitro inhibit ion studies in human liver microsomes suggest that cytochrome P450 (CYP) 1A2, 2C19 and 3A4 are involved in leflunomide metabolism.
Študije zaviranja in vitro z mikrosomi humanih jeter kažejo, da so v presnovo leflunomida vključeni citokromi P450 (CYP) 1A2, 2C19 in 3A4.
In vitro interaction studies did not show any inhibition or induction of the principal isoenzymes of cytochrome P450.
Raziskave interakcij in vitro niso pokazale zaviranja ali indukcije glavnih izoencimov citokroma P450.
In vitro interaction studies to determine the potential inhibitory effects on transporters concluded that there were no clinically relevant effects, except for OAT3.
In vitro študije interakcij, kjer so ugotavljali potencialne zaviralne učinke na prenašalce so pokazale, da ni klinično pomembnih učinkov, razen na OAT3.
in vitro labelling
označevanje in vitro
In vitro ledipasvir inhibits intestinal CYP3A4 and UGT1A1.
Ledipasvir in vitro zavira CYP3A4 in UGT1A1 v črevesju.
In vitro metabolism assays and in vivo studies have demonstrated that there are no pharmacodynamic or pharmacokinetic interactions between fipronil, (S)-methoprene, eprinomectin and praziquantel.
In vitro študije metabolizma ter in vivo študije so pokazale, da med fipronilom, (S)-metoprenom, eprinomektinom in prazikvantelom ni farmakodinamičnih in farmakokinetičnih interakcij.
In vitro metabolism studies have confirmed that the parent compound is rapidly metabolised to 3-O- acetyltylosin.
In vitro študije metabolizma so potrdile, da se prvotna spojina zelo hitro presnavlja v 3-O-acetiltilozin.
In vitro metabolism studies have confirmed that the parent compound is rapidly metabolised to 3-O- acetyltylosin.
Študije presnove in vitro so potrdile, da se izhodna spojina hitro presnovi v 3-O-acetiltilozin.
In vitro metabolism studies in human liver microsomes suggest that DM1, a component of trastuzumab emtansine, is metabolised mainly by CYP3A4 and, to a lesser extent, by CYP3A5.
Študije presnove in vitro v človeških jetrnih mikrosomih kažejo, da se DM1 (sestavina trastuzumaba emtanzina) presnovi v glavnem s CYP3A4 in v manjši meri s CYP3A5.
In vitro metabolism studies in human liver microsomes suggest that DM1, a small molecule component of trastuzumab emtansine, is metabolised mainly by CYP3A4 and to a lesser extent by CYP3A5.
Študije presnove in vitro v človeških jetrnih mikrosomih kažejo, da se DM1, malomolekulska sestavina trastuzumaba emtanzina, presnovi v glavnem s CYP3A4 in v manjši meri s CYP3A5.
In vitro olaparib is a substrate for the efflux transporter P-gp and therefore P-gp inhibitors may increase exposure to olaparib (see section 4.4).
In vitro je olaparib substrat efluksnega prenašalca P-gp, zato lahko zaviralci P-gp povečajo izpostavljenost olaparibu (glejte poglavje 4.4).
In vitro plasma protein binding in human plasma of fluticasone furoate and vilanterol was high, on average >99.6% and 93.9%, respectively.
Vezava na plazemske beljakovine v človeški plazmi in vitro je bila visoka: flutikazonfuroata v povprečju > 99,6 % in vilanterola v povprečju 93,9 %.
In vitro plasma protein binding is low (30%).
V raziskavah in vitro je vezava na plazemske beljakovine dokaj nizka (35%).
In vitro potential for sofosbuvir/velpatasvir drug-drug interations
In vitro potencial za medsebojne interakcije med sofosbuvirjem in velpatasvirjem.
In vitro protein binding of tenofovir to plasma or serum protein was less than 0.7 and 7.2%, respectively, over the tenofovir concentration range 0.01 – 25 μg/ml.
In vitro je bila vezava tenofovirja na plazemske proteine manjša od 0,7% oziroma na serumske proteine manjša od 7,2% v koncentracijskem območju tenofovirja od 0,01 do 25 μg/ml.
In vitro purified enoxaparin has a high anti factor Xa blood clotting (anti-Xa) (approximately 100 IU/mg) and a low anti factor IIa (anti-IIa) or antithrombin (approximately 28 IU / mg).
vitro ima prečiščeni enoksaparin veliko aktivnost anti-Xa pri strjevanju krvi (približno 100 i.e./mg) in majhno aktivnost anti-IIa ter antitrombinsko aktivnost (približno 28 i.e./mg).
In vitro responses seen in single channel patch clamp experiments using membrane patches from rodent cells expressing mutant CFTR forms do not necessarily correspond to in vivo pharmacodynamic response (e.g., sweat chloride) or clinical benefit.
Ni nujno, da odzivi in vitro, ugotovljeni v poskusih z enokanalnim ojačevalnikom »patch clamp«, v katerih so bile uporabljene površine membran glodalskih celic z izraženimi mutantnimi oblikami CFTR, ustrezajo farmakodinamičnemu odzivu in vivo (n.pr. kloridom v znoju) ali klinični koristi.
In vitro studies also demonstrated that eltrombopag is a breast cancer resistance protein (BCRP) substrate and inhibitor.
In vitro študije so tudi pokazale, da je eltrombopag substrat in zaviralec proteina odpornosti za raka dojke (BCRP - breast cancer resistance protein).
In vitro studies also indicated that axitinib has the potential to inhibit CYP2C8.
In vitro študije so pokazale tudi, da aksitinib lahko zavira CYP2C8.
In vitro studies demonstrate that rosiglitazone is predominantly metabolised by CYP2C8, with a minor contribution by CYP2C9.
Študije in vitro so pokazale, da se rosiglitazon pretežno presnavlja s CYP2C8, ob manjšem prispevku CYP2C9.
In vitro studies demonstrated that eltrombopag is a breast cancer resistance protein (BCRP) substrate and inhibitor.
V študijah in vitro so dokazali, da je eltrombopag substrat in zaviralec proteina odpornosti pri raku dojke (BCRP- breast cancer resistance protein).
In vitro studies demonstrated that eltrombopag is not a substrate for the organic anion transporter polypeptide, OATP1B1, but is an inhibitor of this transporter.
In vitro študije so pokazale, da eltrombopag ni substrat za organski anionski prenašalni polipeptid OATP1B1 temveč zaviralec tega prenašalca.
In vitro studies demonstrated that inhibition of the key transporters associated with drug disposition in the kidney (organic anion-transporting polypeptide-1B1 (OATP1B1), OATP1B3, organic anion transporter-1 (OAT1), OAT3 and organic cationic transporter-2 (OCT2)) at exposures following inhalation of 240 mg levofloxacin twice daily is low.
Študije in vitro so pokazale, da je zaviranje ključnih prenašalcev, povezanih z dispozicijo zdravila v ledvicah (transportnega polipeptida organskih anionov 1B1 (OATP1B1), OATP1B3, organskega anionskega prenašalca 1 (OAT1), OAT3 in organskega kationskega prenašalca 2 (OCT2)), ob izpostavljenosti po inhaliranju 240 mg levofloksacina dvakrat na dan nizko.
In vitro studies demonstrated that telaprevir is an inhibitor of OATP1B1 and OATP2B1.
In vitro študije so pokazale, da telaprevir zavira prenašalca OATP1B1 in OATP2B1.
In vitro studies demonstrated that trametinib is metabolised predominantly via deacetylation alone or with mono-oxygenation or in combination with glucuronidation biotransformation pathways.
Študije in vitro so pokazale, da se trametinib presnovi predvsem z deacetilacijo samo ali z monooksigenacijo ali v kombinaciji s potmi glukuronidacijske biotransformacije.
In vitro studies evaluating the percent recovery of total dose delivered with nasogastric, nasojejunal or gastrostomy tubes demonstrated the percent of dose recovered was > 99% for doses > 1 ml and 70% for a 0.5 ml dose.
Študije in vitro, ki so ocenjevale odstotek izkoriščenega skupnega odmerka, ki je bil apliciran preko nazogastrične sonde, nazojejunalne sonde ali gastrostome, so pokazale, da je bil odstotek izkoriščenega odmerka > 99 % za odmerke > 1 ml in približno 70 % za odmerek 0,5 ml.
In vitro studies have also shown that bivalirudin prolongs the activated partial thromboplastin time (aPTT) thrombin time (TT) and pro-thrombin time (PT) of normal human plasma in a concentration- dependent manner and that bivalirudin does not induce a platelet aggregation response against sera from patients with a history of Heparin-Induced Thrombocytopenia/Thrombosis Syndrome (HIT/HITTS).
Študije in vitro kažejo tudi, da bivalirudin od koncentacije odvisno podaljša aktivirani parcialni tromboplastinski čas (aTPČ), trombinski čas (TČ) in protrombinski čas (PČ) normalne človeške plazme in da bivalirudin ne povzroča agregacije krvnih ploščic kot odziv na serum pri bolnikih s heparinsko povzročenim sindromom trombocitopenije/tromboze (HIT/HITTS – »Heparin-Induced Thrombocytopenia/Thrombosis Syndrom«) v anamnezi.
In vitro studies have demonstrated that afatinib is a substrate of P-gp and BCRP.
Raziskave in vitro so pokazale, da je afatinib substrat za P-gp in BCRP.
In vitro studies have demonstrated that LeukoScan has no effect on either up-regulation or down- regulation of granulocytes, but LeukoScan does appear to bind more avidly to activated rather than resting granulocytes.
In vitro študije so pokazale, da zdravilo LeukoScan nima učinka na povišanje ali znižanje števila granulocitov, toda zdi se, da se zdravilo LeukoScan raje veže na aktivirane kot na mirujoče granulocite.
In vitro studies have demonstrated that nalmefene is a selective opioid receptor ligand with antagonist activity at the μ and δ receptors and partial agonist activity at the κ receptor.
Študije in vitro so pokazale, da je nalmefen selektivni ligand opioidnih receptorjev z antagonističnim delovanjem na receptorje μ in δ ter delno agonističnim delovanjem na receptorje κ.
In vitro studies have demonstrated that the Phase I metabolism of osimertinib is predominantly via CYP3A4 and CYP3A5.
Študije in vitro so pokazale, da poteka presnova I. faze osimertiniba pretežno s CYP3A4 in CYP3A5.
In vitro studies have demonstrated that vemurafenib is a substrate of the efflux transporters P-gp and BCRP.
Študije in vitro so pokazale, da je vemurafenib substrat sekretornih prenašalcev, P-gp in BCRP.
In vitro studies have demonstrated that vemurafenib is an inhibitor of the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
Študije in vitro so pokazale, da je vemurafenib zaviralec sekretornih prenašalcev, P-glikoproteina (P-gp) in proteina pri odpornosti raka dojk (BCRP, breast cancer resistance protein).
In vitro studies have determined that neither tenofovir disoproxil fumarate nor tenofovir are substrates for the CYP enzymes.
Študije in vitro so pokazale, da dizoproksiltenofovirijev fumarat in tenofovir nista substrata za encime CYP.
In vitro studies have determined that neither tenofovir disoproxil fumarate nor tenofovir are substrates for the CYP450 enzymes.
In vitro študije so pokazale, da niti dizoproksiltenofovirijev fumarat niti tenofovir nista substrata za CYP450 encime.
In vitro studies have shown methylnaltrexone bromide to be a mu-opioid receptor antagonist (inhibition constant [Ki] = 28 nM), with 8-fold less potency for kappa opioid receptors (Ki = 230 nM) and much reduced affinity for delta opioid receptors.
Študije in vitro so pokazale, da je metilnaltreksonijev bromid antagonist mu-opioidnih receptorjev (inhibicijska konstanta [Ki] = 28 nM), z osemkrat manjšo učinkovitostjo za opioidne receptorje kappa (Ki = 230 nM) in zelo zmanjšano afiniteto za opioidne receptorje delta.
In vitro studies have shown that aclidinium bromide or the metabolites of aclidinium bromide at the therapeutic dose are not expected to cause interactions with P-glycoprotein (P-gp) substrate drugs or drugs metabolised by cytochrome P450 (CYP450) enzymes and esterases (see section 5.2).
V študijah in vitro so pokazali, da se za aklidinijev bromid ali presnovek aklidinijevega bromida v terapevtskem odmerku ne pričakuje medsebojnega delovanja z zdravili, ki so substrati P-glikoproteina (P-gp), ali zdravili, ki jih presnavljajo encimi citokroma P450 (CYP450) in esteraze (glejte poglavje 5.2).
In vitro studies have shown that brivaracetam exhibits little or no inhibition of CYP450 isoforms except for CYP2C19.
Študije in vitro so pokazale, da brivaracetam zavira, malo zavira ali ne zavira, izooblike CYP450 razen CYP2C19.
In vitro studies have shown that ceftaroline is bactericidal and able to inhibit bacterial cell wall synthesis in methicillin-resistant Staphylococcus aureus (MRSA) and penicillin non-susceptible Streptococcus pneumoniae (PNSP) due to its affinity for the altered penicillin-binding proteins (PBPs) found in these organisms.
Študije in vitro so pokazale, da je ceftarolin baktericiden in zmožen, zavreti sintezo bakterijske celične stene v Staphylococcus aureus, odpornemu proti meticilinu (MRSA), in Streptococcus pneumoniae, neobčutljivemu za penicilin (PNSP), in sicer zaradi svoje afinitete za spremenjene penicilin vežoče beljakovine (PBP – penicillin binding proteins) v teh organizmih.
In vitro studies have shown that corticotroph tumour cells from Cushing’s disease patients display a high expression of hsst5, whereas the other receptor subtypes either are not expressed or are expressed at lower levels.
Rezultati študij in vitro so pokazali, da je na kortikotropnih tumorskih celicah bolnikov s Cushingovo boleznijo v velikem obsegu izražena podvrsta receptorja hsst5, medtem ko druge podvrste receptorja sploh niso izražene ali pa so izražene v manjši meri.
In vitro studies have shown that gefitinib is a substrate of p-glycoprotein (Pgp).
Študije in vitro so pokazale, da je gefitinib substrat p-glikoproteina (Pgp).
In vitro studies have shown that indacaterol, a long-acting beta2-adrenergic agonist, has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3- receptors.
Rezultati raziskav in vitro so pokazali, da ima indakaterol, dolgodelujoč agonist adrenergičnih receptorjev beta-2, več kot 24-krat večjo agonistično aktivnost na receptorje beta-2 kot na receptorje beta-1 in 20-krat večjo kot na receptorje beta-3.
In vitro studies have shown that osimertinib is not a substrate of OATP1B1 and OATP1B3.
Študije in vitro so pokazale, da osimertinib ni substrat OATP1B1 in OATP1B3.
In vitro studies have shown that pemetrexed behaves as a multitargeted antifolate by inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are key folate-dependent enzymes for the de novo biosynthesis of thymidine and purine nucleotides.
Študije in vitro so pokazale, da se pemetreksed vede kot večtarčni antifolat z zaviranjem timidilatne sintaze (TS – thymidylate synthase), dihidrofolatne reduktaze (DHFR – dihydrofolate reductase) in glicinamidne ribonukleotidne formiltransferaze (GARFT – glycinamide ribonucleotide formyltransferase), ki so ključni od folata odvisni encimi za de novo biosintezo timidinskih in purinskih nukleotidov.
In vitro studies have shown that plasma protein binding was not relevantly affected by the presence of warfarin, diazepam, digoxin, phenytoin and tolbutamide.
Študije in vitro so pokazale, da prisotnost varfarina, diazepama, digoksina, fenitoina in tolbutamida ne vpliva bistveno na vezavo na beljakovine v plazmi.
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as ciclosporine, ketoconazole and erythromycin .
Študije in vitro so pokazale, da lahko presnovo docetaksela spremeni sočasna uporaba zdravil, ki inducirajo ali inhibirajo citokrom P450-3A ali se z njim presnavljajo (in ga tako lahko kompetitivno inhibirajo), kot so ciklosporin, ketokonazol in eritromicin.
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as ciclosporine, ketoconazole and erythromycin.
Raziskave in vitro so pokazale, da lahko presnovo docetaksela spremeni sočasna uporaba zdravil, ki inducirajo ali inhibirajo citokrom P450-3A ali se z njim presnavljajo (in ga tako lahko kompetitivno inhibirajo); mednje spadajo npr. ciklosporin, ketokonazol in eritromicin.
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as cyclosporine, ketoconazole and erythromycin.
Študije in vitro so pokazale, da lahko presnovo docetaksela spremeni sočasna uporaba zdravil, ki inducirajo ali inhibirajo citokrom P4503A ali jih ta presnavlja (in tako lahko kompetitivno inhibirajo encim), kot so ciklosporin, ketokonazol in eritromicin.
In vitro studies in human hepatocytes also indicated that axitinib does not induce CYP1A1, CYP1A2, or CYP3A4/5.
In vitro študije na človeških hepatocitih so prav tako pokazale, da aksitinib ne inducira CYP1A1, CYP1A2 ali CYP3A4/5.
In vitro studies in human liver microsomes indicate that tedizolid phosphate and tedizolid do not significantly inhibit metabolism mediated by any of the following cytochrome P450 isoenzymes (CYP1A2, CYP2C19, CYP2A6, CYP2C8, CYP2C9, CYP2D6, and CYP3A4).
Študije in vitro na človeških jetrnih mikrosomih kažejo, da tedizolid fosfat in tedizolid bistveno ne zavirata presnove preko katerega koli od naslednjih izoencimov citokroma P450 (CYP1A2, CYP2C19, CYP2A6, CYP2C8, CYP2C9, CYP2D6 in CYP3A4).
In vitro studies in human, dog, mouse and rat plasma showed a high plasma protein binding (> 99.5 %), mainly to albumin and α-1-acid glycoprotein.
Študije in vitro v plazmi ljudi, psov, miši in podgan kažejo na visoko vezavo na beljakovine v plazmi (> 99,5 %), pretežno na albumin in α-1 kisli glikoprotein.
In vitro studies in liver microsomes showed that eluxadoline is not an inhibitor of CYP3A4 at clinically relevant concentrations, but in intestinal microsomes, eluxadoline inhibited CYP3A4 with a Ki of 450 µM (256 µg/mL).
Študije in vitro na jetrnih mikrosomih so pokazale, da eluksadolin ne zavira CYP3A4 pri klinično pomembnih koncentracijah, vendar v črevesnih mikrosomih zavira CYP3A4 s Ki 450 µM (256 µg/ml).